Back

Dapagliflozin and blood pressure control in type 2 diabetes: a meta-analysis of randomised clinical trials

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New insights into antihypertensive treatment Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr A Barbosa

Alfenas (Brazil)

5 More presentations in this session

Presentation thumbnail
Individual patient data pooled analysis of randomised trials in Australia and United States assessing a quadruple combination single pill in patients with hypertension:results from the QUARTET studies
Doctor S. Marschner (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Short-term effects of blood pressure lowering drugs on cardiovascular events: a systematic review and meta-analysis of randomised, placebo-controlled, doubled-blind trials
Doctor S. Gnanenthiran (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Telemonitoring with biweekly telephone intervention enhances blood pressure control in uncontrolled hypertension: a randomized-controlled pilot study.
Doctor P. Sagmeister (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of spironolactone in reducing the risk of cardiovascular events and long-term mortality in those with resistant hypertension: findings from the Anglo-Scandinavian Cardiac Outcomes Trial.
Doctor J. Prashar (London, GB)
Abstract Slides Video
Presentation thumbnail
Different antihypertensive strategies targeting RAAS show opposite outcomes in cerebral injury in hypertensives
Mr L. Carnevale (Pozzilli, IT)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into antihypertensive treatment
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
New insights into antihypertensive treatment
thumbnail
Congress Session
Pharmacological management of hypertension
thumbnail
Congress Presentation
Cardiovascular outcomes in diabetic patients treated with SGLT2i and GLP1-RA: systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources